Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors

Programed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) is a cell surface protein that binds to Programmed Cell Death Protein 1 (PD-1, also known as CD279). An imbalance in PD-1/PD-L1 activity contributes to cancer immune escape.   PD-1 is expressed on the surface of antigen-stimulated T cells. The interaction between PD-L1 and PD-1 negatively regulates T cell-mediated immune responses. It has been suggested that disrupting the PD-L1/PD-1 signaling pathway can be used to treat cancers. The aberrant expression of PD-L1 on mu ltiple tumor types supports this suggestion. As a result, PD-L1 represents a strong target for the development of new anti-cancer therapeutics. Researchers at the NCI ’s Laboratory of Molecular Biology have isolated three anti-PD-L1 single domain antibodies (also known as nanobodies), B2, A11, and F5 that target PD-L1. These nanobodies can be used either as independent agents or as the targeting domain in chimeric antigen receptors (CARs), antibody drug conjuga tes (ADCs), recombinant immunotoxins (RITs), and bispecific antibodies. Significantly, CARs using these antibodies has shown potent in vitro and in vivo killing against PD-L1 positive tumors, including liver and triple-negative breast cancer, strongly supporting that these candidates may be further developed as therapeutics.Inventors: Chi-Ping Day (NCI) Dan Li (NCI) Glenn Merlino (NCI) Hejiao English (NCI) Mitchell Ho (NCI)Commercial Advantages:T...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Tags: Therapeutics Collaboration Sought NCI Source Type: research